Symposium: Update on prediction and management of OHSSPrevention of OHSS – dopamine agonists
Section snippets
Dr Busso is a gynaecologist, specializing in reproductive medicine. He is currently a postgraduate student at the University of Valencia, Spain. He was a fellow of the Reproductive Endocrinology unit of the Instituto Valenciano de Infertilidad – Valencia. His special interests include pathophysiology of ovarian hyperstimulation syndrome and natural and minimal stimulation cycles for ovarian stimulation.
References (78)
- et al.
Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome
Fertility and Sterility
(1997) - et al.
Serum vascular endothelial growth factor concentrations in in-vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome
Fertility and Sterility
(1999) - et al.
Prognostic importance of serial cytokine changes in ascites and pleural effusion in women with severe ovarian hyperstimulation syndrome
Fertility and Sterility
(1999) - et al.
Prospective study of the clinical and laboratory parameters of patients in whom ovarian hyperstimulation syndrome developed during controlled ovarian hyperstimulation for in-vitro fertilization
Fertility and Sterility
(1999) - et al.
Increased capillary permeability induced by human follicular fluid: a hypothesis for an ovarian origin of the hyperstimulation syndrome
Fertility and Sterility
(1995) - et al.
Detection and quantification of complexed and free soluble human vascular endothelial growth factor receptor-1 (sVEGFR-1) by ELISA
Journal of Immunological Methods
(1999) - et al.
Identification of a natural soluble form of the vascular endothelial growth factor receptor, flt-1, and its heterodimerization with KDR
Biochemical and Biophysical Research Communications
(1996) Antihistamine blockade of the ovarian hyperstimulation syndrome
American Journal of Obstetrics and Gynecology
(1974)- et al.
Cabergoline: a safe, easy, cheap, and effective drug for prevention/treatment of ovarian hyperstimulation syndrome?
European Journal of Obstetrics, Gynecology, and Reproductive Biology
(2005) - et al.
Vascular endothelial cell growth factor as permeability agent in ovarian hyperstimulation syndrome
Lancet
(1994)
Direct correlation between plasma renin activity and severity of the ovarian hyperstimulation syndrome
Fertility and Sterility
The pathogenesis of ovarian hyperstimulation syndrome: in-vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor
Fertility and Sterility
The mouse gene for vascular endothelial growth factor. Genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences
Journal of Biological Chemistry
Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy
Neoplasia
Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor
Journal of Biological Chemistry
The ovarian hyperstimulation syndrome
Fertility and Sterility
Elevated levels of angiogenin in serum and ascitic fluid from patients with severe ovarian hyperstimulation syndrome
Human Reproduction
Severe OHSS: An ‘epidemic’ of severe OHSS: a price we have to pay?
Human Reproduction
The role of the endothelium in the pathogenesis of ovarian hyperstimulation syndrome
Molecular Human Reproduction
Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction
Journal of Clinical Endocrinology and Metabolism
Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study
Human Reproduction
The vascular character of ovarian follicular granulosa cells: phenotypic and functional evidence for an endothelial-like cell population
Human Reproduction
The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor
Nature Medicine
Ovarian hyperstimulation syndrome: a review of pathophysiology
Journal of Assisted Reproduction and Genetics
Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice
Cancer Research
Expression of messenger ribonucleic acid splice variants for the vascular endothelial growth factor in the penis of adult rats and humans
Biology of Reproduction
Quinagolide is effective in preventing moderate/severe early OHSS in IFV patients: a randomized, double-blind, placebo controlled trial
Human Reproduction
A spontaneous and severe hyperstimulation of the ovaries revealing a gonadotroph adenoma
Journal of Clinical Endocrinology and Metabolism
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor
Science
New insights into the pathophysiology of ovarian hyperstimulation syndrome. What makes the difference between spontaneous and iatrogenic syndrome?
Human Reproduction
Dopamine treatment for severe ovarian hyperstimulation syndrome
Human Reproduction
The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome
Journal of Clinical Endocrinology and Metabolism
VEGF blocking therapy in the treatment of cancer
Expert Opinion Biology Therapy
Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model
Endocrinology
Administration of moderate and high doses of gonadotrophins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability
Biology of Reproduction
Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade
Endocrinology
Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation
Journal of Clinical Endocrinology and Metabolism
Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor
Proceedings of the National Academy of Sciences of the United States of America
Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas
Fertility and Sterility
Cited by (38)
Ovarian hiperstimulation syndrome: Incidence in a public service of assisted reproduction and literature review
2013, Reproducao e ClimaterioCitation Excerpt :Several studies indicate that the development of OHSS is mediated by the presence of human chorionic gonadotropin (hCG), exogenous or endogenous.5 The administration of hCG would lead to an increased vascular permeability, mediated by the receptors of vascular endothelial growth factor (VEGF) present in the theca-cells and granulosa.5,10,11 Prostaglandins, inhibin, mediators of the inflammatory system and activation of the renin-angiotensin-aldosterone system are also factors involved in the etiology of OHSS.5,12
The importance of anti-Müllerian hormone in infertility
2012, Reproducao e ClimaterioPredictive Value of Serum Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor in Ovarian Hyperstimulation Syndrome
2012, Journal of Reproduction and ContraceptionReply of the authors
2011, Fertility and SterilityDopamine agonist bromocriptine for the prevention of ovarian hyperstimulation syndrome
2011, Fertility and Sterility
Dr Busso is a gynaecologist, specializing in reproductive medicine. He is currently a postgraduate student at the University of Valencia, Spain. He was a fellow of the Reproductive Endocrinology unit of the Instituto Valenciano de Infertilidad – Valencia. His special interests include pathophysiology of ovarian hyperstimulation syndrome and natural and minimal stimulation cycles for ovarian stimulation.
Declaration: The authors report no financial or commercial conflicts of interest.